STOPDAPT-2 Risk Subgroup Calculator

Age (years) Acute coronary syndrome (ACS) presentation? Select Yes No High-bleeding-risk (HBR) criteria met? Select Yes No Complex PCI (yes/no)?

Select Yes No STOPDAPT-2 ACS Risk Subgroup Calculator: Explanation and Clinical Context The STOPDAPT-2 family of trials investigated the safety and efficacy of abbreviated dual antiplatelet therapy (DAPT) duration followed by P2Y12 inhibitor monotherapy versus standard 12-month DAPT in patients undergoing percutaneous coronary intervention (PCI) using cobalt‐chromium everolimus-eluting stents (CoCr-EES). Subgroup analyses explored how key clinical variables (such as presentation with acute coronary syndrome [ACS], high bleeding risk [HBR], and complexity of PCI) modify risks of ischemic or bleeding events, offering insight into patient stratification though not producing a formal numeric risk-score formula. In the ACS subgroup, 1- to 2-month DAPT followed by clopidogrel monotherapy did not meet noninferiority compared with 12-month DAPT for the composite endpoint, trending toward higher ischemic risk (HR ~1.50) despite reduced major bleeding (HR ~0.46) at 1-year.

Accordingly, in clinical practice, patients with ACS, HBR, or complex PCI may require a more cautious DAPT approach. This calculator uses simplified multipliers to estimate a 1-year composite risk (ischemic + bleeding) based on these modifiers; it should not replace formal guideline-driven individualized decision making.